Bleeding after menopause is not automatically cancer, but it is never a symptom to diagnose by internet reassurance. In Canada, the purpose of the pathway is to identify the source and rule out endometrial precancer or cancer without pretending that the uterus is the only place blood can come from.
IN THIS ARTICLE
What counts as postmenopausal bleeding?
Any vaginal bleeding, spotting or blood-stained discharge after 12 months without a natural menstrual period should be reported. Bleeding on menopausal hormone therapy has additional timing and regimen considerations, but persistent, heavy, late-onset or recurrent bleeding still requires assessment. Do not stop prescribed MHT abruptly unless the prescriber advises it; report the bleeding and the exact regimen.
How urgent?
Contact primary care or the prescribing clinician promptly. Go to urgent or emergency care for soaking-heavy bleeding, fainting, chest pain, shortness of breath, severe pain, marked weakness or signs of haemodynamic instability. Otherwise, this is usually an urgent outpatient investigation—not a reason to assume the worst overnight.
What usually happens next
Bleeding happens → contact a clinician → history and examination → ultrasound and/or endometrial sampling as appropriate → results interpreted with the full clinical picture → persistent or recurrent bleeding may need hysteroscopy or further evaluation.
Plain English: no single symptom, ultrasound measurement or biopsy result answers every case. The sequence narrows the possibilities, and bleeding that returns deserves another look.
The Canadian pathway, in plain language
| Stage | What may happen | Question being answered |
|---|---|---|
| 1. Confirm the source | History; medication/MHT review; vulvar, vaginal and speculum examination; cervical screening status; sometimes urine or rectal assessment | Is the blood actually vaginal, and is there a visible lower-tract cause? |
| 2. Assess uterus and endometrium | Transvaginal ultrasound and/or office endometrial biopsy; practice varies by risk and access | Is the lining thin and uniform? Is sampled tissue benign? |
| 3. Investigate focal or unresolved findings | Saline-infusion sonography or hysteroscopy with targeted biopsy/removal | Is there a polyp, submucosal fibroid or area a blind biopsy could miss? |
| 4. Act on pathology | Gynaecology or gynaecologic-oncology referral when hyperplasia/EIN/cancer is found | What treatment and staging are needed? |
| 5. Reassess recurrence | Further evaluation even after an initially reassuring test when bleeding returns | Was a focal lesion missed, or has the clinical picture changed? |
Where the ‘4 mm rule’ fits—and where it does not
Many pathways use a thin, clearly visualized endometrium on transvaginal ultrasound—often 4 mm or less—as strongly reassuring in an initial episode. Thresholds and practice differ with MHT, risk factors and newer guidance. The measurement is not a universal all-clear: the stripe may be poorly seen, ultrasound may miss focal disease, and recurrent bleeding can justify tissue sampling or hysteroscopy despite a thin measurement.
Do not confuse this with guidance about an incidental thickened endometrium in someone who is not bleeding. Canadian recommendations for asymptomatic findings use a different risk framework. Symptoms change the question.
What it may be other than cancer
| Possible cause | How it causes bleeding | How it is investigated |
|---|---|---|
| Vaginal or endometrial atrophy / GSM | Thin, fragile low-estrogen tissue can tear or spot | Examination; ultrasound/biopsy as appropriate before attributing uterine bleeding |
| Endometrial or cervical polyp | Fragile focal tissue bleeds intermittently | Ultrasound may suggest it; saline sonography or hysteroscopy is better for focal lesions |
| Fibroid, especially submucosal | Distorts or irritates the cavity | Ultrasound and sometimes hysteroscopy |
| MHT-related bleeding | Endometrium responds to regimen, dose, missed progesterone or adjustment period | Exact medication timeline plus appropriate imaging/sampling |
| Cervical/vulvar/vaginal disease | Inflammation, trauma, polyp, dysplasia or cancer | Direct examination, cervical testing/colposcopy when indicated |
| Infection or trauma | Inflamed or injured tissue bleeds | History, examination and targeted tests |
| Urinary or rectal source | Blood is mistaken for vaginal bleeding | Urinalysis, examination or gastrointestinal assessment |
| Endometrial hyperplasia/EIN | Excess growth, sometimes with atypical cells | Endometrial tissue diagnosis |
| Endometrial cancer or other malignancy | Abnormal tissue bleeds | Biopsy; hysteroscopy and oncology pathway when confirmed |
Most postmenopausal bleeding has a benign explanation; the pathway exists because symptoms alone cannot reliably separate benign causes from cancer.
What to record before the appointment
- Date, colour, amount, duration and whether bleeding followed sex or exertion.
- Every hormone product: estrogen route/dose, progesterone name/dose/schedule, vaginal estrogen, testosterone and missed doses.
- Anticoagulants, tamoxifen and supplements.
- Pain, discharge, fever, urinary or bowel symptoms and unexplained weight change.
- Last natural period, prior bleeding investigations, cervical screening and relevant family history.
- Risk factors such as diabetes, obesity, Lynch syndrome or prolonged unopposed estrogen exposure.
If sampling is recommended, Inside the Test explains what an office endometrial biopsy can find, what an insufficient sample means and why a blind sample can miss a focal lesion. Use the menopause appointment checklist to bring the bleeding timeline, medication list and your priority questions.
Why a benign biopsy may not be the end
A blind office biopsy samples tissue well for diffuse disease but may miss a focal polyp or fibroid. If bleeding recurs, the sample was insufficient, ultrasound is irregular, or the lining cannot be adequately visualized, direct cavity assessment may be reasonable. A 2026 joint-society guideline concluded that hysteroscopy with visually directed biopsy has higher diagnostic accuracy than blind sampling for several focal and premalignant conditions.
Bleeding that occurs while using menopausal hormone therapy still needs context: the regimen, timing, duration and individual risk factors all matter. The Canadian overview of menopausal hormone therapy explains why systemic estrogen requires appropriate uterine protection when a uterus is present.
Access in Canada
A family physician, nurse practitioner, walk-in/urgent primary-care clinician or MHT prescriber can begin the workup and refer to gynaecology. Access and ordering rules vary by province and region; some clinics arrange ultrasound first, others biopsy first, and some do both. If you cannot obtain timely primary care, provincial 811 services can help identify appropriate local access, but they do not replace the investigation.
Sources and further reading
- BC guideline: Endometrial Cancer—Diagnosis and Management
- Investigation of women with postmenopausal uterine bleeding: clinical recommendations
- Visually directed hysteroscopic biopsy guideline (2026)
- Endometrial biopsy: tips, performance and limitations
- Rapid recommendations summarizing the 2024 SOGC asymptomatic-endometrium guideline
- Ontario Health Menopause Quality Standard
Educational information only
This article is for education and does not diagnose, treat or replace care from a qualified health professional. Seek urgent care for severe or rapidly worsening symptoms.